Home › Compare › JMCCF vs ABBV
JMCCF yields 1775064.68% · ABBV yields 3.06%● Live data
📍 JMCCF pulled ahead of the other in Year 1
Combined, JMCCF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of JMCCF + ABBV for your $10,000?
JAMCO Corporation manufactures and sells aircraft interiors, seats, and components in Japan. The company offers aircraft interior products, including galleys and bar counters; lavatories comprising touch-less faucets, counters, mirrors and lights, bidet systems, and touch-less flush switches; galley inserts consisting of steam ovens; and flight deck linings, consoles, and stowage, as well as seats and seat consoles. It also provides aircraft components, which includes heat exchangers and chassis for electronic equipment; aircraft engine parts, such as cooling manifolds, engine pipes, turbine shrouds, and outer transition liner products; and stringers and stiffeners for vertical tails. In addition, the company offers aircraft maintenance services for small-sized aircraft and helicopters and regional aircraft; and aircraft accessories maintenance services for system components, rescue hoists, wheels and brakes, high pressure gas cylinder, emergency evacuation slides, and cabin equipment and atmospheric observation equipment. Further, it provides nondestructive testing, welding, composites, and laser machining services. The company was formerly known as New Japan Aircraft Maintenance Co., Ltd. and changed its name to JAMCO Corporation in June 1988. JAMCO Corporation was incorporated in 1949 and is headquartered in Tachikawa, Japan.
Full JMCCF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.